.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,620,689

« Back to Dashboard

Details for Patent: 5,620,689

Title: Liposomes for treatment of B-cell and T-cell disorders
Abstract:A method of treating a subject having a disorder characterized by a neoplasm of B-lymphocyte or T-lymphocyte lineage cells is described. The method includes administering a suspension of liposomes having a surface coating of polyethylene glycol chains. Attached to the distal ends of the chains are antibodies or antibody fragments effective to bind to an antigen specific to the affected cells. In one embodiment, anti-CD19 antibodies are attached to the liposome-bound chains, for treatment of multiple myeloma.
Inventor(s): Allen; Theresa M. (Edmonton, CA), Martin; Francis J. (San Francisco, CA)
Assignee: Sequus Pharmaceuuticals, Inc. (Menlo Park, CA)
Filing Date:Jun 07, 1995
Application Number:08/475,050
Claims:1. A method of treating a subject having a disorder characterized by a neoplasm of B-lymphocyte lineage cells or T-lymphocyte lineage cells, comprising

administering to the subject, a suspension of liposomes having a surface coating of polyethylene glycol chains effective to increase the blood circulation lifetime of the liposomes severalfold over that of liposomes in the absence of such coating, a chemotherapeutic agent in liposome-entrapped form, and covalently attached to the distal ends of a portion of said chains, antibodies or antibody fragments effective to bind to an antigen specific for said cells.

2. The method of claim 1, wherein said administering includes administration of liposomes having an attached antibody selected from the group consisting of anti-CD19 , anti-CD20 and anti-CD22, for binding to a B-cell antigen.

3. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD19 antibody, and said disorder is multiple myeloma.

4. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD19 antibody, and said disorder is acute lymphocytic leukemia.

5. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD19 antibody, and said disorder is a B-cell lymphoma.

6. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD20 antibody, and said disorder is multiple myeloma.

7. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD20 antibody, and said disorder is acute lymphocytic leukemia.

8. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD20 antibody, and said disorder is a B-cell lymphoma.

9. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD22 antibody, and said disorder is multiple myeloma.

10. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD22 antibody, and said disorder is acute lymphocytic leukemia.

11. The method of claim 2, wherein said administering includes administration of liposomes having an attached anti-CD22 antibody, and said disorder is a B-cell lymphoma.

12. The method of claim 2, wherein said administering includes administration to a subject having multiple myeloma, and said cells are multidrug resistant.

13. The method of claim 1, wherein said administering includes administration of liposomes having an attached antibody selected from the group consisting of anti-CD4 and anti-CD8, for binding to a T-cell antigen.

14. The method of claim 13, wherein said administering includes administration of liposomes having an attached anti-CD4 antibody, and said disorder is a T-cell lymphoma.

15. The method of claim 13, wherein said administering includes administration of liposomes having an attached anti-CD4 antibody and said disorder is acute lymphocytic leukemia.

16. The method of claim 1, wherein said administering includes administration of liposomes having a coating of polyethylene glycol having a molecular weight of between about 500-10,000 daltons.

17. The method of claim 1, wherein said administering includes administration of liposomes having a coating of polyethylene glycol having a molecular weight of between about 500-2,000 daltons.

18. The method of claim 1, wherein said administering includes administration of liposomes having doxorubicin in liposome entrapped form.

19. The method of claim 1, wherein said administering includes administration of liposomes having vincristine in liposome entrapped form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc